everolimus post pazopanib treatment in metastatic or advanced renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma. due to changes in the rcc treatment landscape, info gained is no longer clinically relevant to patients. data collected is deemed sufficient to meet objective.

a non-randomised, open label, single-arm phase ii study to evaluate the efficacy and safety of 1st-line pazopanib followed by 2nd-line everolimus in patients with previously untreated advanced or metastatic renal cell carcinoma. subjects received initial therapy with pazopanib followed, on progression, by 2nd-line therapy with everolimus. study treatment - sequential treatment with pazopanib followed by everolimus - to continue until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Eligibility criteria:
inclusion criteria: * age \>=18 years * histologically confirmed rcc with a clear-cell component * locally advanced or metastatic rcc * at least one measurable lesion per recist 1.1 criteria, as determined by computer tomography (ct) scan or magnetic resonance imaging (mri) * no systemic therapy for advanced or metastatic rcc prior to enrollment * karnofsky performance status (kps) ≥70 * adequate baseline organ function * a female was eligible to enter and participate in this study if she was of: non-childbearing potential, or negative serum pregnancy test with agreement to use adequate contraception during the study * a male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from 2 weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment * able to swallow and retain orally administered medication and must not have clinically significant gi abnormalities that may alter absorption additional inclusion criteria for starting everolimus: * disease progression must be within 6 months after stopping pazopanib * at least one measurable lesion at the start of everolimus pe r recist 1.1 criteria, as determined by ct or mri * in case of central nervous system (cns) progression or metastasis during pazopanib treatment: asymptomatic or neurologically stable, no requirement of steroids to control cns symptoms, and no requirement of enzyme-inducing anticonvulsants within 4 weeks prior to the start of everolimus exclusion criteria: * lactating female * history of another malignancy (exception: patients disease-free for ≥3 years and patients with completely resected non-melanoma skin cancer or successfully treated in situ carcinoma) * symptomatic cns metastases at baseline * clinically significant gastrointestinal abnormalities * moderate to severe hepatic impairment (child pugh class c) * receiving chronic treatment with corticosteroids/other immunosuppressive agents * active bleeding, bleeding diathesis or on oral anti-vitamin k medication (except low dose coumadin) * corrected qt interval (qtc) \>480 msec using bazett's formula * presence of any severe or uncontrolled medical conditions/infection * poorly controlled hypertension (defined as systolic blood pressure of \>=140mmhg or diastolic blood pressure of \>=90mmhg) * history of cardiovascular disorders within the last 12 months (e.g. myocardial infraction or unstable angina), history of cerebrovascular events or pulmonary embolism within the last 6 months * active bleeding or bleeding susceptibility * known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increased the risk of pulmonary hemorrhage additional criteria for exclusion from the second-line everolimus treatment period: - the subject felt by the investigator to be unsuitable (on the basis of health, compliance, or for any other reason) for inclusion in the study.

Keywords: renal cell carcinoma (rcc), gw786034, everolimus, pazopanib, renal cancer, cancer, kidney cancer, hypernephroma, grawitz tumor, renal adenocarcinoma.